Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.14 Consensus PT from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have received a consensus recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $15.14.

A number of research analysts recently weighed in on CATX shares. Royal Bank of Canada restated an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer lowered their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 24th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, UBS Group began coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 8,000 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the transaction, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. This represents a 28.31 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heidi Henson purchased 25,975 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was bought at an average price of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now owns 25,975 shares of the company’s stock, valued at $100,003.75. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have bought 67,570 shares of company stock valued at $256,789 in the last ninety days. Corporate insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics during the fourth quarter valued at $33,000. Aigen Investment Management LP bought a new position in Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI raised its position in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares during the period. ProShare Advisors LLC lifted its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics in the fourth quarter worth about $51,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Down 1.4 %

Shares of NYSE:CATX opened at $2.92 on Thursday. Perspective Therapeutics has a 1-year low of $2.70 and a 1-year high of $19.05. The firm’s 50 day simple moving average is $3.34 and its two-hundred day simple moving average is $8.57.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.